{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:22:41Z","timestamp":1793247761235,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41401-020-0409-3","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T06:03:32Z","timestamp":1591077812000},"page":"1547-1556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Icariside II attenuates cerebral ischemia\/reperfusion-induced blood\u2013brain barrier dysfunction in rats via regulating the balance of MMP9\/TIMP1"],"prefix":"10.1038","volume":"41","author":[{"given":"Mu-bo","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-mei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-shan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-hai","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"409_CR1","doi-asserted-by":"crossref","first-page":"7150376","DOI":"10.1155\/2017\/7150376","volume":"2017","author":"QY Zhang","year":"2017","unstructured":"Zhang QY, Wang ZJ, Sun DM, Wang Y, Xu P, Wu WJ, et al. Novel therapeutic effects of leonurine on ischemic stroke: new mechanisms of BBB integrity. Oxid Med Cell Longev. 2017;2017:7150376.","journal-title":"Oxid Med Cell Longev"},{"key":"409_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.phrs.2019.04.017","volume":"144","author":"U Bayraktutan","year":"2019","unstructured":"Bayraktutan U. Endothelial progenitor cells: potential novel therapeutics for ischaemic stroke. Pharmacol Res. 2019;144:181\u201391.","journal-title":"Pharmacol Res."},{"key":"409_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1474-4422(15)00337-3","volume":"15","author":"KW Muir","year":"2016","unstructured":"Muir KW. Stroke in 2015: the year of endovascular treatment. Lancet Neurol. 2016;15:2\u20133.","journal-title":"Lancet Neurol."},{"key":"409_CR4","first-page":"75","volume":"10","author":"SN Chapman","year":"2014","unstructured":"Chapman SN, Mehndiratta P, Johansen MC, McMurry TL, Johnston KC, Southerland AM. Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke. Vasc Health Risk Manag. 2014;10:75\u201387.","journal-title":"Vasc Health Risk Manag"},{"key":"409_CR5","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awx111","volume":"140","author":"L Mao","year":"2017","unstructured":"Mao L, Li P, Zhu W, Cai W, Liu Z, Wang Y, et al. Regulatory T cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke. Brain. 2017;140:1914\u201331.","journal-title":"Brain."},{"key":"409_CR6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.brainres.2017.10.024","volume":"1678","author":"H Karatas","year":"2018","unstructured":"Karatas H, Eun Jung J, Lo EH, van Leyen K. Inhibiting 12\/15-lipoxygenase to treat acute stroke in permanent and tPA induced thrombolysis models. Brain Res. 2018;1678:123\u20138.","journal-title":"Brain Res."},{"key":"409_CR7","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1161\/STROKEAHA.108.514026","volume":"39","author":"Y Murata","year":"2008","unstructured":"Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke. 2008;39:3372\u20137.","journal-title":"Stroke."},{"key":"409_CR8","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/jcbfm.2009.105","volume":"29","author":"L Zhang","year":"2009","unstructured":"Zhang L, Chopp M, Jia L, Cui Y, Lu M, Zhang ZG. Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J Cereb Blood Flow Metab. 2009;29:1816\u201324.","journal-title":"J Cereb Blood Flow Metab"},{"key":"409_CR9","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1007\/s12035-014-8952-x","volume":"52","author":"W Wang","year":"2015","unstructured":"Wang W, Li M, Chen Q, Wang J. Hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke: mechanisms, models, and biomarkers. Mol Neurobiol. 2015;52:1572\u20139.","journal-title":"Mol Neurobiol"},{"key":"409_CR10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.biotechadv.2015.02.004","volume":"33","author":"H Peluffo","year":"2015","unstructured":"Peluffo H, Unzueta U, Negro-Demontel ML, Xu Z, Vaquez E, Ferrer-Miralles N, et al. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS. Biotechnol Adv. 2015;33:277\u201387.","journal-title":"Biotechnol Adv."},{"key":"409_CR11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.arcmed.2014.11.018","volume":"45","author":"P Campos-Bedolla","year":"2014","unstructured":"Campos-Bedolla P, Walter FR, Veszelka S, Deli MA. Role of the blood-brain barrier in the nutrition of the central nervous system. Arch Med Res. 2014;45:610\u201338.","journal-title":"Arch Med Res"},{"key":"409_CR12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nbd.2009.07.033","volume":"37","author":"P Jeffrey","year":"2010","unstructured":"Jeffrey P, Summerfield S. Assessment of the blood\u2013brain barrier in CNS drug discovery. Neurobiol Dis. 2010;37:33\u20137.","journal-title":"Neurobiol Dis."},{"key":"409_CR13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neulet.2016.06.003","volume":"627","author":"LL Kong","year":"2016","unstructured":"Kong LL, Wang ZY, Hu JF, Yuan YH, Li H, Chen NH. Inhibition of chemokine-like factor 1 improves blood-brain barrier dysfunction in rats following focal cerebral ischemia. Neurosci Lett. 2016;627:192\u20138.","journal-title":"Neurosci Lett."},{"key":"409_CR14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.pneurobio.2017.10.001","volume":"163-164","author":"X Jiang","year":"2018","unstructured":"Jiang X, Andjelkovic AV, Zhu L, Yang T, Bennett MVL, Chen J, et al. Blood-brain barrier dysfunction and recovery after ischemic stroke. Prog Neurobiol. 2018;163-164:144\u201371.","journal-title":"Prog Neurobiol."},{"key":"409_CR15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.nbd.2010.03.008","volume":"38","author":"R Jin","year":"2010","unstructured":"Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood\u2013brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis. 2010;38:376\u201385.","journal-title":"Neurobiol Dis."},{"key":"409_CR16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.nbd.2008.08.005","volume":"32","author":"KE Sandoval","year":"2008","unstructured":"Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis. 2008;32:200\u201319.","journal-title":"Neurobiol Dis."},{"key":"409_CR17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lfs.2015.01.006","volume":"126","author":"C Li","year":"2015","unstructured":"Li C, Li Q, Mei Q, Lu T. Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii. Life Sci. 2015;126:57\u201368.","journal-title":"Life Sci."},{"key":"409_CR18","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.biochi.2012.06.033","volume":"94","author":"D Zhang","year":"2012","unstructured":"Zhang D, Zhang J, Fong C, Yao X, Yang M. Herba Epimedii flavonoids suppress osteoclastic differentiation and bone resorption by inducing G2\/M arrest and apoptosis. Biochimie. 2012;94:2514\u201322.","journal-title":"Biochimie."},{"key":"409_CR19","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.phymed.2014.07.016","volume":"21","author":"YQ Liu","year":"2014","unstructured":"Liu YQ, Yang QX, Cheng MC, Xiao HB. Synergistic inhibitory effect of icariside II with icaritin from Herba Epimedii on pre-osteoclastic RAW264.7 cell growth. Phytomedicine. 2014;21:1633\u20137.","journal-title":"Phytomedicine."},{"key":"409_CR20","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1159\/000493229","volume":"49","author":"S Liu","year":"2018","unstructured":"\u00a0Liu S, Li X, Gao J, Liu Y, Shi J, Gong Q. Icariside II, a phosphodiesterase-5 inhibitor, attenuates beta-amyloid-induced cognitive deficits via BDNF\/TrkB\/CREB signaling. Cell Physiol Biochem. 2018;49:985.","journal-title":"Cell Physiol Biochem"},{"key":"409_CR21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.biopha.2018.10.201","volume":"111","author":"J Zhou","year":"2019","unstructured":"Zhou J, Deng Y, Li F, Yin C, Shi J, Gong Q. Icariside II attenuates lipopolysaccharide-induced neuroinflammation through inhibiting TLR4\/MyD88\/NF-kappaB pathway in rats. Biomed Pharmacother. 2019;111:315\u201324.","journal-title":"Biomed Pharmacother."},{"key":"409_CR22","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bph.14912","volume":"177","author":"J Gao","year":"2020","unstructured":"Gao J, Long L, Xu F, Feng L, Liu Y, Shi J, et al. Icariside II, a phosphodiesterase 5 inhibitor, attenuates cerebral ischemia\/reperfusion injury by inhibiting GSK-3\u03b2-mediated activation of autophagy. Br J Pharmacol. 2020;177:1434\u201352.","journal-title":"Br J Pharmacol"},{"key":"409_CR23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuint.2016.02.015","volume":"96","author":"Y Deng","year":"2016","unstructured":"Deng Y, Xiong D, Yin C, Liu B, Shi J, Gong Q. Icariside II protects against cerebral ischemia reperfusion injury in rats via nuclear factor-kB inhibition and peroxisome proliferator activated receptor up-regulation. Neurochem Int. 2016;96:56\u201361.","journal-title":"Neurochem Int."},{"key":"409_CR24","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.2174\/138161212802002670","volume":"18","author":"CV Borlongan","year":"2012","unstructured":"Borlongan CV, Rodrigues AA Jr, Oliveir MC. Breaking the barrier in stroke: what should we know? A mini-review. Curr Pharmacol Des. 2012;18:3615\u201323.","journal-title":"Curr Pharmacol Des"},{"key":"409_CR25","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1161\/STROKEAHA.107.505420","volume":"39","author":"A Kastrup","year":"2008","unstructured":"Kastrup A, Groschel K, Ringer TM, Redecker C, Cordesmeyer R, Witte O, et al. Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke. Stroke. 2008;39:2385\u20137.","journal-title":"Stroke."},{"key":"409_CR26","doi-asserted-by":"crossref","first-page":"8237","DOI":"10.1523\/JNEUROSCI.1089-04.2004","volume":"24","author":"I Potrovita","year":"2004","unstructured":"Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, Wang M, et al. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci. 2004;24:8237\u201344.","journal-title":"J Neurosci."},{"key":"409_CR27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/jcbfm.2013.203","volume":"34","author":"GC Jickling","year":"2014","unstructured":"Jickling GC, Liu D, Stamova B, Ander B, Zhan X, Lu A, et al. Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab. 2014;34:185\u201399.","journal-title":"J Cereb Blood Flow Metab"},{"key":"409_CR28","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/ATVBAHA.109.195370","volume":"30","author":"JW Gaubatz","year":"2010","unstructured":"Gaubatz JW, Ballantyne CM, Wasserman BA, He M, Chambless LE, Boerwinkle E, et al. Association of circulating matrix metalloproteinases with carotid artery characteristics: the atherosclerosis risk in communities carotid MRI study. Arterioscler Thromb Vasc Biol. 2010;30:1034\u201342.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"409_CR29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.matbio.2017.11.007","volume":"75-76","author":"MJ Hannocks","year":"2019","unstructured":"Hannocks MJ, Zhang X, Gerwien H, Chashchina A, Burmeister M, Korpos E, et al. The gelatinases, MMP-2 and MMP-9, as fine tuners of neuroinflammatory processes. Matrix Biol. 2019;75-76:102\u201313.","journal-title":"Matrix Biol."},{"key":"409_CR30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.cardiores.2005.12.002","volume":"69","author":"H Nagase","year":"2006","unstructured":"Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562\u201373.","journal-title":"Cardiovasc Res."},{"key":"409_CR31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.archoralbio.2017.10.003","volume":"85","author":"H J\u00e4sberg","year":"2018","unstructured":"J\u00e4sberg H, Tervahartiala T, Sorsa T, S\u00f6derling E, Haukioja A. Probiotic intervention influences the salivary levels of matrix metalloproteinase (MMP)-9 and tissue inhibitor of metalloproteinases (TIMP)-1 in healthy adults. Arch Oral Biol. 2018;85:58\u201363.","journal-title":"Arch Oral Biol"},{"key":"409_CR32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.semcancer.2010.05.002","volume":"20","author":"D Bourboulia","year":"2010","unstructured":"Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20:161\u20138.","journal-title":"Semin Cancer Biol"},{"key":"409_CR33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.pjnns.2018.05.005","volume":"52","author":"J Zielinska-Turek","year":"2018","unstructured":"Zielinska-Turek J, Dorobek M, Turek G, Barcikowska-Kotowicz M. MMP-9 and\/or TIMP as predictors of ischaemic stroke in patients with symptomatic and asymptomatic atherosclerotic stenosis of carotid artery treated by stenting or endarterectomy - a review. Neurol Neurochir Pol. 2018;52:555\u201361.","journal-title":"Neurol Neurochir Pol"},{"key":"409_CR34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0167-4838(99)00279-4","volume":"1477","author":"K Brew","year":"2000","unstructured":"Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267\u201383.","journal-title":"Biochim Biophys Acta"},{"key":"409_CR35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jtemb.2019.08.001","volume":"56","author":"R Nosrati","year":"2019","unstructured":"Nosrati R, Kheirouri S, Ghodsi R, Ojaghi H. The effects of zinc treatment on matrix metalloproteinases: a systematic review. J Trace Elem Med Biol. 2019;56:107\u201315.","journal-title":"J Trace Elem Med Biol"},{"key":"409_CR36","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/jcbfm.2008.59","volume":"28","author":"M Fujimoto","year":"2008","unstructured":"Fujimoto M, Takagi Y, Aoki T, Hayase M, Marumo T, Gomi M, et al. Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischemia. J Cereb Blood Flow Metab. 2008;28:1674\u201385.","journal-title":"J Cereb Blood Flow Metab"},{"key":"409_CR37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s12031-014-0441-1","volume":"55","author":"H Wei","year":"2015","unstructured":"Wei H, Wang S, Zhen L, Yang Q, Wu Z, Lei X, et al. Resveratrol attenuates the blood-brain barrier dysfunction by regulation of the MMP-9\/TIMP-1 balance after cerebral ischemia reperfusion in rats. J Mol Neurosci. 2015;55:872\u20139.","journal-title":"J Mol Neurosci"},{"key":"409_CR38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.brainres.2013.11.031","volume":"1544","author":"Y Liu","year":"2014","unstructured":"Liu Y, Wang D, Wang H, Qu Y, Xiao X, Zhu Y. The protective effect of HET0016 on brain edema and blood\u2013brain barrier dysfunction after cerebral ischemia\/reperfusion. Brain Res. 2014;1544:45\u201353.","journal-title":"Brain Res."},{"key":"409_CR39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/187152708784936608","volume":"7","author":"RM Adibhatla","year":"2008","unstructured":"Adibhatla RM, Hatcher JF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets. 2008;7:243\u201353.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"409_CR40","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jep.2014.06.015","volume":"155","author":"S Fu","year":"2014","unstructured":"Fu S, Gu Y, Jiang JQ, Chen X, Xu M, Chen X, et al. Calycosin-7-O-\u03b2-D-glucoside regulates nitric oxide\/caveolin-1\/matrix metalloproteinases pathway and protects blood\u2013brain barrier integrity in experimental cerebral ischemia\u2013reperfusion injury. J Ethnopharmacol. 2014;155:692\u2013701.","journal-title":"J Ethnopharmacol."},{"key":"409_CR41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.expneurol.2017.12.016","volume":"302","author":"XF Li","year":"2018","unstructured":"Li XF, Zhang XJ, Zhang C, Wang LN, Li Y, Zhang Y, et al. Ulinastatin protects brain against cerebral ischemia\/reperfusion injury through inhibiting MMP-9 and alleviating loss of ZO-1 and occludin proteins in mice. Exp Neurol. 2018;302:68\u201374.","journal-title":"Exp Neurol."},{"key":"409_CR42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ilar.44.2.85","volume":"44","author":"RJ Traystman","year":"2003","unstructured":"Traystman RJ. Animal models of focal and global cerebral ischemia. ILAR J. 2003;44:85\u201395.","journal-title":"ILAR J."},{"key":"409_CR43","first-page":"197","volume":"25","author":"YM Zhang","year":"2012","unstructured":"Zhang YM, Zhou Y, Qiu LB, Ding GR, Pang XF. Altered expression of matrix metalloproteinases and tight junction proteins in rats following PEMF-induced BBB permeability change. Biomed Environ Sci. 2012;25:197\u201302.","journal-title":"Biomed Environ Sci"},{"key":"409_CR44","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejphar.2019.04.021","volume":"854","author":"C Li","year":"2019","unstructured":"Li C, Wang X, Cheng F, Du X, Yan J, Zhai C, et al. Geniposide protects against hypoxia\/reperfusion-induced blood-brain barrier impairment by increasing tight junction protein expression and decreasing inflammation, oxidative stress, and apoptosis in an in vitro system. Eur J Pharmacol. 2019;854:224\u201331.","journal-title":"Eur J Pharmacol"},{"key":"409_CR45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.201412147","volume":"209","author":"S Tietz","year":"2015","unstructured":"Tietz S, Engelhardt B. Brain barriers: crosstalk between complex tight junctions and adherens junctions. J Cell Biol. 2015;209:493\u2013506.","journal-title":"J Cell Biol"},{"key":"409_CR46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pneurobio.2017.12.001","volume":"161","author":"J Lv","year":"2018","unstructured":"Lv J, Hu W, Yang Z, Li T, Jiang S, Ma Z, et al. Focusing on claudin-5: a promising candidate in the regulation of BBB to treat ischemic stroke. Prog Neurobiol. 2018;161:79\u201396.","journal-title":"Prog Neurobiol."},{"key":"409_CR47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.semcdb.2014.11.004","volume":"38","author":"RF Haseloff","year":"2015","unstructured":"Haseloff RF, Dithmer S, Winkler L, Wolburg H, Blasig IE. Transmembrane proteins of the tight junctions at the blood\u2013brain barrier: structural and functional aspects. Semin Cell Dev Biol. 2015;38:16\u201325.","journal-title":"Semin Cell Dev Biol"},{"key":"409_CR48","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0166-2236(00)02004-X","volume":"24","author":"JD Huber","year":"2001","unstructured":"Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 2001;24:719\u201325.","journal-title":"Trends Neurosci"},{"key":"409_CR49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.brainresbull.2018.11.006","volume":"144","author":"Y Li","year":"2019","unstructured":"Li Y, Zhong W, Jiang Z, Tang X. New progress in the approaches for blood-brain barrier protection in acute ischemic stroke. Brain Res Bull. 2019;144:46\u201357.","journal-title":"Brain Res Bull"},{"key":"409_CR50","doi-asserted-by":"crossref","first-page":"108619","DOI":"10.1016\/j.biopha.2019.108619","volume":"112","author":"IH EI Khashab","year":"2019","unstructured":"EI Khashab IH, Abdelsalam RM, Elbrairy AI, Attia AS. Chrysin attenuates global cerebral ischemic reperfusion injury via suppression of oxidative stress, inflammation and apoptosis. Biomed Pharmacother. 2019;112:108619.","journal-title":"Biomed Pharmacother."},{"key":"409_CR51","doi-asserted-by":"crossref","first-page":"re6","DOI":"10.1126\/scisignal.127re6","volume":"1","author":"WG Stetler-Stevenson","year":"2008","unstructured":"Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008;1:re6.","journal-title":"Sci Signal"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0409-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0409-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0409-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T20:06:34Z","timestamp":1722974794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-0409-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-0409-3","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]},"assertion":[{"value":"18 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}